表皮生长因子过表达与宫颈癌预后相关性Meta分析  

Prognostic significance of EGFR in cervical cancer:a Mata-analysis

作　　者：郑兴[1,2] 杜雪莲[1] 

机构地区：[1]山东省肿瘤医院妇科,山东济南250117 [2]济南大学.山东省医学科学院医学与生命科学学院,山东济南250000

出　　处：《中华肿瘤防治杂志》2015年第16期1321-1327,1334,共8页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省科技发展计划(2013YD18028)

摘　　要：目的评价表皮生长因子受体（epidermalgrowthfactorreceptor，EGFR）过表达在宫颈癌预后中的价值，为抗EGFR靶向治疗提供理论依据。方法计算机检索PubMed和Embase数据库以及中国知网、维普和万方数据库中有关EGFR表达与宫颈癌的文献，采用ReviewManager4．3软件进行分析。EGFR过表达与淋巴结转移、临床分期和病理类型采用合并比值比（oddsratio，OR）及95％可信区间（confidenceinterval，CI）进行分析。总生存期（overallsurvival，0S）及无病生存期（diseasefreesurvival，DFS）采用风险比（hazardratio，HR）及95％CI进行分析。结果入选20篇文献纳入研究，显示EGFR与淋巴结转移有关，OR=1.68，95％CI为1．16～2．44，P=0．006；与国际妇产科联盟（InternationalFederationofGynecologyandObstetries，FIG0）分期有关，0R=1．66，95％CI为1．12～2．46，P=0．02；与病理类型有关，0R=4．79，95％CI为2．35～9．76，P〈0．001；与0s有关，HR=1．33，95％CI为1．15～1．53，P〈0．001；与DFS有关，HR=1．36，95％CI为1．12～1．65，P=0．002。EGFR与年龄无关，OR=1．20，95％CI为0．84～1．71，P=0．19。结论EGFR的过表达对淋巴结转移、OS及DFS有预测价值，可能是宫颈癌不良预后的预测因子，EGFR靶向治疗可考虑作为宫颈癌综合治疗的方法。OBJECTIVE To assess the value of epidermal growth factor receptor （EGFR） overexpression in the prognosis of cervical cancer and to provide theoretical base for anti-EGFR targeting therapy. METHODS PubMed, EM- base, CNKI, Weipu and Wanfang database were searched for studies on the correlation between EGFR expression and prognosis of cervical cancer until December 2014. All analyses were calculated by software Review Manager 4.3. Lymph node metastasis（LNM）, Federation International of Gynecology and Obstetrics （FIGO） stage, histological type and age were analyzed using pooled odds ratio（OR） with 95% confidence interval（CI）. Overall survival （OS） and disease free sur- vival （DFS） were analyzed using pooled hazard ratio （HR） with 95%CI. RESULTS A total of 20 studies were enrolled in this Meta analysis. The results showed EGFR overexpression was correlated with LNM （OR= 1.68, 95% CI： 1.16- 2.44, P=0. 006）, FIGO stage （OR=1. 66,95%CI：1. 12-2.46,P=0.02）, histological type （OR=4.79, 95%CI： 2.35-9.76, P〈0.001）, OS （HR=I. 33,95%CI：I. 15-1.53, P〈0. 001） and DFS （HR：1. 36, 95%CI：1.12-1. 65, P=0. 002）. The expression of EGFR had no relation with age （OR=1. 20, 95% CI： 0.84-1.71, P=0.19）. CONCLUSIONS EGFR overexpression is probably a valuable predictor for LNM, OS and DFS, and it could be used as a poor prognosis indicator for cervical cancer patients. Anti-EGFR targeting therapy should be considered to the comprehensive treatment in cervical cancer.

关 键 词：宫颈癌 表皮生长因子 预后因素 META分析 

分 类 号：R737.33[医药卫生—肿瘤]